FDA Approves KERENDIA (Finerenone) to Reduce the Risk of Sustained EGFR Decline, End Stage Kidney Disease, Cardiovascular Death, Non-Fatal Myocardial Infarction, and Hospitalization for Heart Failure in Adult Patients with CKD Associated with T2D

label